Abstract
Phisiological activation of PI3K pathway is necessary for cells to regulate many different physiological processes such as transcription, protein synthesis, metabolic responses and membrane trafficking. Abnormal activation of the PI3K pathway leads to an increased activity resulting in tumor onset, maintenance, progression and invasion. Both genetic and epigenetic alterations could affect the normal pathways activation. Ovarian cancer is the leading cause of death from gynaecological malignancies in the western world. PI3K pathway has been recorded as one of the most deregulated signalling pathway in many tumors, including ovarian ones. So it could be considered an attractive target to be investigated with the various classes of chemical compounds already present or in development. In this rewiew well try to discuss the published data of the inhibitors targeting members of the PI3K/ akt/ mTOR pathway in the ovarian cancer setting from a preclinical and clinical point of view, with particular emphasis on drugs combination and strategies of administration. Relevant issues and limitations to the use of particular compounds will be also addressed.
Keywords: PI3K, mTOR, anti-cancer drugs, drug combination, gynaecological malignancies, Ovarian cancer, malignancy, receptor tyrosine kinases (RTKs), G protein-coupled receptors, phosphorylate phosphoinositides (PIs), Pleckstrin Homology, tuberous sclerosis, signaling nodes, PI3K INHIBITORS, synergistic effects, paclitaxel, carboplatin, tumor xenografts, glucose homeostasis, phosphoinositide, API-2, macrolide Rapamycin, bevacizumab, Topotecan, pegylated doxorubicin, PI3K-like kinase (PIKK), chemotherapy, angiogenesis, hypoxia, metformin, rapalogs, regimens
Current Medicinal Chemistry
Title: PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Volume: 17 Issue: 36
Author(s): M. Mazzoletti and M. Broggini
Affiliation:
Keywords: PI3K, mTOR, anti-cancer drugs, drug combination, gynaecological malignancies, Ovarian cancer, malignancy, receptor tyrosine kinases (RTKs), G protein-coupled receptors, phosphorylate phosphoinositides (PIs), Pleckstrin Homology, tuberous sclerosis, signaling nodes, PI3K INHIBITORS, synergistic effects, paclitaxel, carboplatin, tumor xenografts, glucose homeostasis, phosphoinositide, API-2, macrolide Rapamycin, bevacizumab, Topotecan, pegylated doxorubicin, PI3K-like kinase (PIKK), chemotherapy, angiogenesis, hypoxia, metformin, rapalogs, regimens
Abstract: Phisiological activation of PI3K pathway is necessary for cells to regulate many different physiological processes such as transcription, protein synthesis, metabolic responses and membrane trafficking. Abnormal activation of the PI3K pathway leads to an increased activity resulting in tumor onset, maintenance, progression and invasion. Both genetic and epigenetic alterations could affect the normal pathways activation. Ovarian cancer is the leading cause of death from gynaecological malignancies in the western world. PI3K pathway has been recorded as one of the most deregulated signalling pathway in many tumors, including ovarian ones. So it could be considered an attractive target to be investigated with the various classes of chemical compounds already present or in development. In this rewiew well try to discuss the published data of the inhibitors targeting members of the PI3K/ akt/ mTOR pathway in the ovarian cancer setting from a preclinical and clinical point of view, with particular emphasis on drugs combination and strategies of administration. Relevant issues and limitations to the use of particular compounds will be also addressed.
Export Options
About this article
Cite this article as:
Mazzoletti M. and Broggini M., PI3K/AKT/mTOR Inhibitors In Ovarian Cancer, Current Medicinal Chemistry 2010; 17 (36) . https://dx.doi.org/10.2174/092986710794182999
DOI https://dx.doi.org/10.2174/092986710794182999 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alginate Bead-Encapsulated PEDF Induces Ectopic Bone Formation In Vivo in the Absence of Co-Administered Mesenchymal Stem Cells
Current Drug Targets Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: 'A Hard Days Night'
Current Pharmaceutical Design Quantitative Analysis of Acidic Polysaccharides Using Hydrophilic Interaction Chromatography and Mass Spectrometry after Acid Hydrolysis
Current Pharmaceutical Analysis Medical Implications of Benzimidazole Derivatives as Drugs Designed for Targeting DNA and DNA Associated Processes
Current Medicinal Chemistry pH-Sensitive PEGylated Liposomes Functionalized With a Fibronectin-Mimetic Peptide Show Enhanced Intracellular Delivery to Colon Cancer Cells
Current Pharmaceutical Biotechnology Phosphodiesterase 3 (PDE3): Structure, Localization and Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Progress in the Development of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Texaphyrins: Tumor Localizing Redox Active Expanded Porphyrins
Anti-Cancer Agents in Medicinal Chemistry Aryltetralin-type Lignan of Podophyllum: A Comprehensive Review
The Natural Products Journal From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals Copper Complexes of 8-Aminoquinoline and Uracils as Novel Aromatase Inhibitors
Letters in Drug Design & Discovery Recent Advances in Multinuclear Complexes as Potential Anticancer and DNA Binding Agents
Anti-Cancer Agents in Medicinal Chemistry Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets Bacteria and Bacterial Toxins as Therapeutic Agents for Solid Tumors
Current Cancer Drug Targets Dextran-based Nanocarriers for Delivery of Bioactives
Current Pharmaceutical Design Rapid Desensitization of Hypersensitivity Reactions to Chemotherapy Agents.
Current Drug Safety Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets